The latest price target for Edgewise Therapeutics (NASDAQ:EWTX) was reported by RBC Capital on September 20, 2024. The analyst firm set a price target for $42.00 expecting EWTX to rise to within 12 months (a possible 48.46% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Edgewise Therapeutics (NASDAQ:EWTX) was provided by RBC Capital, and Edgewise Therapeutics maintained their outperform rating.

There is no last upgrade for Edgewise Therapeutics

The last downgrade for Edgewise Therapeutics Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $5 for Edgewise Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.

While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a maintained with a price target of $32.00 to $42.00. The current price Edgewise Therapeutics (EWTX) is trading at is $28.29, which is out of the analyst’s predicted range.